Illumina (NASDAQ:ILMN) doesn't command the respect and awe of investors like it has in the past. Its stock performance reflects this reality, with the genomic-sequencing pioneer's shares down 6% year to date.
The company announced its third-quarter results after the market closed on Thursday. But did those results improve Illumina's standing with investors? Here are the highlights from the company's Q3 update.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,